| Dr Megan Beth Thiel, | |
|
2299 Highway 49, Beulah, ND 58523-9165 | |
| (701) 880-8923 | |
| Not Available |
| Full Name | Dr Megan Beth Thiel |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 2299 Highway 49, Beulah, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053087056 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | R34893 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi St Alexius Health Dickinson | Dickinson, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St. Joseph's Hospital And Health Center | 0547177560 | 76 |
News Archive
At the III International Symposium on Advanced Therapy for Chronic Inflammatory Bowel Disease, held in Madrid, the biotechnological company, Progenika, presented a DNA-chip the purpose of which is the optimisation of the diagnosis, prognosis and treatment of patients with inflammatory bowel disease (Crohn's disease and Ulcerous Colitis).
For adults with diabetes, managing the disease is a day-in, day-out effort to control the factors that affect blood sugar levels.
People who are stressed by daily problems or trouble at work seem to be more likely to grind their teeth at night. Researchers writing in BioMed Central's open access journal Head & Face Medicine studied the causes of 'sleep bruxism', gnashing teeth during the night, finding that it was especially common in those who try to cope with stress by escaping from difficult situations.
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.
CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR).
› Verified 7 days ago
| Entity Name | St. Joseph's Hospital And Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730464108 PECOS PAC ID: 0547177560 Enrollment ID: O20031107000651 |
News Archive
At the III International Symposium on Advanced Therapy for Chronic Inflammatory Bowel Disease, held in Madrid, the biotechnological company, Progenika, presented a DNA-chip the purpose of which is the optimisation of the diagnosis, prognosis and treatment of patients with inflammatory bowel disease (Crohn's disease and Ulcerous Colitis).
For adults with diabetes, managing the disease is a day-in, day-out effort to control the factors that affect blood sugar levels.
People who are stressed by daily problems or trouble at work seem to be more likely to grind their teeth at night. Researchers writing in BioMed Central's open access journal Head & Face Medicine studied the causes of 'sleep bruxism', gnashing teeth during the night, finding that it was especially common in those who try to cope with stress by escaping from difficult situations.
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.
CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Megan Beth Thiel, 2299 Highway 49, Beulah, ND 58523-9165 Ph: (701) 880-8923 | Dr Megan Beth Thiel, 2299 Highway 49, Beulah, ND 58523-9165 Ph: (701) 880-8923 |
News Archive
At the III International Symposium on Advanced Therapy for Chronic Inflammatory Bowel Disease, held in Madrid, the biotechnological company, Progenika, presented a DNA-chip the purpose of which is the optimisation of the diagnosis, prognosis and treatment of patients with inflammatory bowel disease (Crohn's disease and Ulcerous Colitis).
For adults with diabetes, managing the disease is a day-in, day-out effort to control the factors that affect blood sugar levels.
People who are stressed by daily problems or trouble at work seem to be more likely to grind their teeth at night. Researchers writing in BioMed Central's open access journal Head & Face Medicine studied the causes of 'sleep bruxism', gnashing teeth during the night, finding that it was especially common in those who try to cope with stress by escaping from difficult situations.
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.
CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR).
› Verified 7 days ago
Kelsey Leigh Striefel, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1312 Highway 49 N, Beulah, ND 58523 Phone: 701-873-4445 Fax: 701-873-4199 | |
Laurie Huston, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1101 3rd Ave Nw, Beulah, ND 58523 Phone: 701-873-4242 | |
Abbey Pelton, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1312 Highway 49 N, Beulah, ND 58523 Phone: 701-873-4445 | |
Mrs. Debra Leigh Sailer, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1312 Highway 49 N, Beulah, ND 58523 Phone: 701-873-4445 Fax: 701-873-4199 | |
Stacy Lynn Johnson, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 420 Cty Rd. 26, Beulah, ND 58523 Phone: 701-873-6788 | |
Sharon Olson, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1312 Hwy 49 Nw, Beulah, ND 58523 Phone: 701-873-4445 Fax: 701-873-4199 |